Source: Υπουργείο Υγείας (CY) Revision Year: 2018 Publisher: MEDOCHEMIE LTD, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus
Rifasynt 150 mg capsules.
Rifasynt 300 mg capsules.
| Pharmaceutical Form |
|---|
|
Rifasynt 150 mg: Hard gelatin capsules, scarlet – scarlet size 2, for oral administration. Rifasynt 300 mg: Hard gelatin capsules, scarlet – scarlet size 1, for oral administration. |
Each capsule contains either 150 mg or 300 mg of rifampicin.
Excipients with known effect: lactose monohydrate.
For the full list of excipients, see section 6.1.
Each 150mg capsule contains lactose monohydrate 23.0mg.
Each 300mg capsule contains lactose monohydrate 28.0mg.
| Active Ingredient | Description | |
|---|---|---|
| Rifampicin |
Rifampicin is an active bactericidial antituberculosis drug which is particularly active against the rapidly growing extracellular organisms and also has bactericidial activity intracellularly. Rifampicin inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. |
| List of Excipients |
|---|
|
Rifasynt 150 mg capsules also contain lactose monohydrate, croscarmellose sodium and magnesium stearate. The capsule shells contain gelatin, erythrosine (E127), indigo carmine (E132) and titanium dioxide (E171). Rifasynt 300 mg capsules also contain lactose monohydrate, croscarmellose sodium and magnesium stearate. The capsule shells contain gelatin, erythrosine (E127), indigo carmine (E132) and titanium dioxide (E171). |
Capsules are available packed in aluminium foil – polyvinylchloride film blisters.
Rifasynt 150mg caps: Cartons containing 8, 10 and 100 capsules are available.
Rifasynt 300mg caps: Cartons containing 8, 20, 100 capsules and hospital packs of 1000 capsules are available.
Not all pack sizes may be marketed.
MEDOCHEMIE LTD, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus
Rifasynt 150mg caps: 8533
Rifasynt 300mg caps: 7238
Rifasynt 150mg caps: 30/10/1982
Rifasynt 300mg caps: 14/12/1979
| Drug | Countries | |
|---|---|---|
| RIFASYNT | Cyprus, Estonia, Hong Kong, Malta |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
